Future Impact of mRNA Therapy on Cardiovascular Diseases.
Future Impact of mRNA Therapy on Cardiovascular Diseases.
复制标题
DOI：
10.14797/mdcvj.1169
复制
发表时间：
2022
影响因子：
--
通讯作者：
Youker, Keith A
中科院分区：
文献类型：
--
作者：
Cooke, John P;Youker, Keith A
最近大流行的一线希望是，它加速了信使核糖核酸(MRNA)疗法的出现。疫苗的产生、测试和证明相对安全和高效的速度突显了信使核糖核酸疗法的巨大前景。目前有各种各样的信使核糖核酸疗法正在开发中，其中数十种正在进行临床试验。这些疗法正在引起包括心血管疾病治疗在内的医学治疗的重大范式转变。大多数心血管信使核糖核酸治疗仍处于临床前开发阶段，尽管治疗心肌缺血的信使核糖核酸治疗2a期试验已经完成，结果令人振奋。信使核糖核酸疗法在心血管疾病中的应用几乎是无限的，正在进行的工作包括心肌缺血、心力衰竭、心律失常、高胆固醇血症和动脉闭塞疾病的信使核糖核酸疗法。此外，信使核糖核酸可能被用来加强细胞治疗。在未来，心血管疾病的信使核糖核酸疗法注定会取代我们目前的一些生物制剂和药物疗法，并将用于治疗以前无法治愈的心血管疾病。此外，信使核糖核酸疗法可以是个性化的，它们可以在目前的良好制造实践设施中以适度的足迹快速产生，促进以医院为基础的区域核糖核酸疗法中心的崛起。
The silver lining of the recent pandemic was that it accelerated the emergence of messenger ribonucleic acid (mRNA) therapeutics. The great promise of mRNA therapeutics was highlighted by the speed at which the vaccines were created, tested, and proven to be relatively safe and highly effective. There are a wide variety of mRNA therapeutics now under development, and dozens of these are in clinical trials. These therapeutics are generating a major paradigm shift in medical therapy, including the treatment of cardiovascular disease. Most of the cardiovascular mRNA therapies are still in preclinical development, although a phase 2a trial of mRNA therapy for myocardial ischemia has been completed with promising results. The application of mRNA therapies to cardiovascular diseases is virtually limitless, and ongoing work includes mRNA therapies for myocardial ischemia, heart failure, arrhythmias, hypercholesterolemia, and arterial occlusive diseases. In addition, mRNA may be used to enhance cell therapies. In the future, mRNA therapies for cardiovascular disease are destined to supplant some of our current biologics and pharmacotherapies and will be used to treat previously untreatable cardiovascular diseases. Furthermore, mRNA therapies can be personalized, and they can be rapidly generated in current Good Manufacturing Practice facilities with a modest footprint, facilitating the rise of hospital-based regional centers of RNA therapeutics.